Development of Lung Vibration Equipment

Not Applicable

Recruiting

• Conditions: Sputum Removal

• Registration Number: NCT07056764
• Lead Sponsor: Burapha University

Brief Summary

This study designed a portable and easily accessible lung vibration device that is simple to use and can operate with both a battery system and a charging system for greater convenience. It helps enhance the effectiveness of mucus drainage, prevents complications, and reduces both the duration and cost of hospital treatment.

Detailed Description

Lung vibration device uses a motor as the power source to generate vibrations and has a shape similar to an iron. It is connected by an electrical cord in this section and can operate using either a battery system or a charging system. It features a vertically aligned handle perpendicular to the main body for a firm grip. The base of the device has a sponge head to absorb shock from the vibration during use, which is removable. The on/off switch is located at the end of the handle. This device uses 220-volt alternating current. The unit weighs approximately 1.1 kilograms and is made of strong and durable plastic.

Study Timeline

• Study Start: 2025-02-08
• Study First Submitted: 2025-06-30
• Study First Submitted QC: 2025-06-30
• Status Verified: 2025-07
• Study First Posted: 2025-07-09
• Last Update Submitted: 2025-07-09
• Last Update Posted: 2025-07-14
• Primary Completion: 2025-09-30
• Study Completion: 2025-09-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

• Male or female
• Aged 18-59 years
• Inpatients at Burapha University Hospital, Mueang District, Chonburi Province, with pulmonary secretion retention
• Referred by their attending physician for enhanced secretion clearance through physical therapy methods

Exclusion Criteria

• Having inflamed wounds on the chest or back
• Having unstable vital signs, defined as: resting heart rate <60 or >100 beats per minute; blood pressure <90/60 or >120/80 mmHg; respiratory rate <12 or >20 breaths per minute; oxygen saturation <95%; and body temperature >37°C
• Having a bleeding tendency, defined as a platelet count <20,000 per cubic millimeter
• Taking medications that increase bleeding risk within 7 days prior to participation, including: Anticoagulants (such as Warfarin, Dabigatran, Rivaroxaban, Apixaban, Edoxaban), Antiplatelet agents (such as Aspirin, Clopidogrel, Dipyridamole, Prasugrel, Ticagrelor)
• Having an International Normalized Ratio (INR) >1.1 for those not on anticoagulants, and >3.0 for those on anticoagulants
• Having subcutaneous emphysema
• Experiencing severe hemoptysis (coughing up blood)
• Having chest wall pain
• Having acute spinal cord injury, rib fractures, or conditions associated with high fracture risk
• Having skin grafts or burn wounds
• Being admitted to intensive care units (ICU, RICU, or CICU)
• Having untreated pneumothorax
• Having an acute inflammatory process of the respiratory system
• Having inflammatory or infectious conditions such as tuberculosis, lung abscess, or COVID-19
• Having respiratory diseases that are contraindications or precautions for lung vibration, including COPD, uncomplicated pneumonia, asthma, lung cancer, or metastatic cancer

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
Systolic blood pressure	Baseline (0 minutes) and immediately post-intervention (30 minutes)	Systolic blood pressure will be measured in mmHg unit
Diastolic blood pressure	Baseline (0 minutes) and immediately post-intervention (30 minutes)	Diastolic blood pressure will be measured in mmHg unit
Body temperature	Baseline (0 minutes) and immediately post-intervention (30 minutes)	Body temperature will be measured in degree Celsius
Oxygen saturation	Baseline (0 minutes) and immediately post-intervention (30 minutes)	Partial pressure of oxygen saturation will be measured in percent
Sputum	Immediately post-intervention (30 minutes)	Sputum will be measured for its quantity in ml unit and quality using photograph

Trial Locations

Locations (1)

Burapha University Hospital; 🇹🇭 Mueang, Chonburi, Thailand

Burapha University Hospital

🇹🇭Mueang, Chonburi, Thailand

Piyapong Prasertsri, Ph.D.

Contact

6638103166

piyapong@buu.ac.th

Tadsawiya Padkao, Ph.D.

Contact

6638103166

tadsawiya@go.buu.ac.th